Metraipolis › archive › dc_710072bb966b

Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy — Europe PMC PMID:41210307

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41210307
DOI
10.3389/falgy.2025.1661047
License (as archived)
solo-consultazione
Archived
2026-11-09T02:40:49.557Z
SHA-256 of the archived text
abd060bc03cb06093f72541187bdb716e7bc9cb21e6d6df2a999df77779e6132
Stable URL of this page
https://metraipolis.com/documento/dc_710072bb966b

How to cite

Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy — Europe PMC PMID:41210307 — Europe PMC (en), https://europepmc.org/article/MED/41210307 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_710072bb966b (Metraipolis archive dc_710072bb966b, sha256 abd060bc03cb06093f72541187bdb716e7bc9cb21e6d6df2a999df77779e6132)
BibTeX
@misc{dc710072bb966b,
  title = {Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy — Europe PMC PMID:41210307},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41210307},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_710072bb966b; sha256 abd060bc03cb06093f72541187bdb716e7bc9cb21e6d6df2a999df77779e6132},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41210307. Agents can read the archived copy with the MCP tool read_document.